Eric Lefkofsky Efforts in the Identification and Early Treatment of Cancer

By | November 9, 2017

There has been an ongoing Medical research carried out by a Dartmouth research team led by the guidance of Yafang Li, with the focus on finding evidence that gene-smoking interactions have a vital role in the etiology of the cancer of the lung. From this research is it conclusive that both environmental and genetic factors are the primary factors that lead to the development of cancer. The smoking of Tobacco is the most common environmental risk factor that is related to lung cancer

During this study, the researchers singled out three SNPs which are also variations in an individual’s DNA underlie his/her vulnerability to developing cancer. These SNPs were identified during the interaction analysis. There were two unique SNPs found which are associated with non-small cell lung cancer risk while one additional SNP is associated with the squamous cell lung cancer risk. The recently discovered SNPs play a vital role in the risk screening and intervention of cancerous cells as they can be used as potential candidate biomarkers for lung cancer screening. The reports of this study that mainly majored on the Caucasian population has been published in the Carcinogenesis.

OnocoArray Consortium supplied both the genotype and phenotype data that was used to conduct this study. So far, this is the most extensive genome-wide interaction analysis performed with the use of SNPs in the study of lung cancer. What made the research a success was the adoption of a two-step strategy that enabled the reduction of power loss that would take place in the standard gene-environment interaction analysis.

The discovered SNPs can be used in the stratification of lung cancer through smoking behavior. It is worth noting that medical researchers can use the SNPs as biomarkers that can be used to improve the precision and accuracy doctors can categorize a person’s risk of developing cancer through smoking; this has proved to be helpful in both the prognosis and the prediction of a patient’s treatment plan.

Eric Lefkofsky is the founder and current chief executive officer at Tempus, a firm that has made significant investments in battling cancer. Other than this Eric is also a founder at Lightbank which many regards to be a venture capitalist firm that funds disruptive technologies. Over the years he has developed a keen entrepreneurial interest making him one of the highly regarded business people in the health and wellness sector. Recently he and a colleague founded Groupon which is an e-commerce platform that is available on a global scale. He has supported various charitable causes through his family foundation which was established in 2006.

Facebook: https://www.facebook.com/eplefkofsky/

Leave a Reply

Your email address will not be published.